Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Impax Laboratories, Inc. (Nasdaq: IPXL) (“Impax” or the “Company”) relating to the all-stock-merger of Impax with Amneal Pharmaceuticals LLC. Under the terms of the agreement, Impax shareholders will own 25% of the new company’s shares and Amneal Holdings members will own 75%. ...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Impax Laboratories, Inc. (Nasdaq: IPXL) (“Impax” or the “Company”) relating to the all-stock-merger of Impax with Amneal Pharmaceuticals LLC. Under the terms of the agreement, Impax shareholders will own 25% of the new company’s shares and Amneal Holdings members will own 75%. ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of Impax Laboratories, Inc. (NASDAQ GS: IPXL)? Did you purchase any of your shares prior to October 17, 2017? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Impax Laboratories, Inc. (“Impax” or the “Company”) (NASDAQ GS: IPXL) ...
CORPORATES ISSUER COMMENT 23 October 2017 Contacts Morris Borenstein +1.212.553.1409 AVP-Analyst [email protected] Impax Laboratories, Inc. Impax and Amneal’s All-Stock Merger Is Credit Positive From Credit Outlook Last Tuesday, generic drug manufacturers Impax Laboratories Inc.  (B2 review for upgrade) and Amneal Pharmaceuticals, LLC  (B1 stable) announced p
WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of Impax Laboratories, Inc. (NASDAQ GS: IPXL)? Did you purchase any of your shares prior to October 17, 2017? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Impax Laboratories, Inc. (“Impax” or the “Company”) (NASDAQ GS: IPXL) ...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Impax Laboratories, Inc. (“Impax” or the “Company”) (NASDAQ: IPXL) stock prior to October 17, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Impax to Amneal Pharmaceuticals LLC. Under the terms of the transaction, shareholders of Impax will receive shares in Amneal and ultimately own approximately 25% of...
CORPORATES CREDIT OPINION 18 April 2017 Update RATINGS Impax Laboratories, Inc. Domicile California, United States Long Term Rating B2 Type LT Corporate Family Ratings Outlook Stable Please see the ratings section at the end of this report for more information. The ratings and outlook shown reflect information as of the publication date. Contacts Peter H. Abdill, CFA
NEW ORLEANS--(BUSINESS WIRE)-- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until January 9, 2017 to file lead plaintiff applications in securities class action lawsuits against Impax Laboratories Inc. (NasdaqGS: IPXL). Investor losses must relate to purchases of the Company’s securities between February 20, 2014 and November 3, 2016. The actions are pending in the United States District Court for the ...
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the January 9, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of a class (the “Class”) of investors who purchased Impax Laboratories, Inc. (“Impax” or the “Company”) (NASDAQ: IPXL) securities between February 25, 2014 and November 3, 2016, inclusive (the “Class Period”). Impax investors have until January 9, 2017 to file a lead plaintiff motion. According to the complaint filed in this lawsuit Defe...
NEW YORK--(BUSINESS WIRE)-- Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Impax Laboratories, Inc. (NASDAQ:IPXL) securities between February 20, 2014 and November 3, 2016 (the “Class Period”). The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Impax was and/or had ...
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Impax Laboratories, Inc. (“Impax” or the “Company”) (NASDAQ: IPXL) securities between February 25, 2014 and November 3, 2016, inclusive (the “Class Period”). Impax investors have until January 9, 2017 to file a lead plaintiff motion. Investors suffering losses on their Impax investments are encouraged to contact Lesley Portnoy of GPM to discus...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Impax Laboratories, Inc. (NASDAQ: IPXL) between February 25, 2014 and November 3, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information go to: http://www.zlk.com/pslra/impax-laboratories or contact Joseph E. Levi, Esq. either via em...
NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Impax Laboratories, Inc. (NASDAQ:IPXL) securities between February 25, 2014 and November 3, 2016. Click here to learn about the case: http://www.wongesq.com/pslra/impax-laboratories. There is no cost or obligation to you. According to the complaint, during the Class Period the Company made false and/or misleading statements ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.